106 related articles for article (PubMed ID: 25380171)
1. Differential antigen expression profile predicts immunoreactive subset of advanced ovarian cancers.
Eng KH; Tsuji T
PLoS One; 2014; 9(11):e111586. PubMed ID: 25380171
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of an immune gene-set based Prognostic signature in ovarian cancer.
Shen S; Wang G; Zhang R; Zhao Y; Yu H; Wei Y; Chen F
EBioMedicine; 2019 Feb; 40():318-326. PubMed ID: 30594555
[TBL] [Abstract][Full Text] [Related]
3. Tumor antigens and markers for breast and ovarian cancers.
Ghadersohi A; Chitta K; Greco WR; Harvey S; Winston J; Slocum H; Odunsi K; Sood AK
Front Biosci; 2002 Feb; 7():e48-57. PubMed ID: 11815284
[TBL] [Abstract][Full Text] [Related]
4. Two microRNA signatures for malignancy and immune infiltration predict overall survival in advanced epithelial ovarian cancer.
Korsunsky I; Parameswaran J; Shapira I; Lovecchio J; Menzin A; Whyte J; Dos Santos L; Liang S; Bhuiya T; Keogh M; Khalili H; Pond C; Liew A; Shih A; Gregersen PK; Lee AT
J Investig Med; 2017 Oct; 65(7):1068-1076. PubMed ID: 28716985
[TBL] [Abstract][Full Text] [Related]
5. High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway.
Yoshihara K; Tsunoda T; Shigemizu D; Fujiwara H; Hatae M; Fujiwara H; Masuzaki H; Katabuchi H; Kawakami Y; Okamoto A; Nogawa T; Matsumura N; Udagawa Y; Saito T; Itamochi H; Takano M; Miyagi E; Sudo T; Ushijima K; Iwase H; Seki H; Terao Y; Enomoto T; Mikami M; Akazawa K; Tsuda H; Moriya T; Tajima A; Inoue I; Tanaka K;
Clin Cancer Res; 2012 Mar; 18(5):1374-85. PubMed ID: 22241791
[TBL] [Abstract][Full Text] [Related]
6. Cancer-testis antigen expression is shared between epithelial ovarian cancer tumors.
Garcia-Soto AE; Schreiber T; Strbo N; Ganjei-Azar P; Miao F; Koru-Sengul T; Simpkins F; Nieves-Neira W; Lucci J; Podack ER
Gynecol Oncol; 2017 Jun; 145(3):413-419. PubMed ID: 28392126
[TBL] [Abstract][Full Text] [Related]
7. Ovarian cancer tumor infiltrating T-regulatory (T(reg)) cells are associated with a metastatic phenotype.
Barnett JC; Bean SM; Whitaker RS; Kondoh E; Baba T; Fujii S; Marks JR; Dressman HK; Murphy SK; Berchuck A
Gynecol Oncol; 2010 Mar; 116(3):556-62. PubMed ID: 20006900
[TBL] [Abstract][Full Text] [Related]
8. T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma.
Leivonen SK; Pollari M; Brück O; Pellinen T; Autio M; Karjalainen-Lindsberg ML; Mannisto S; Kellokumpu-Lehtinen PL; Kallioniemi O; Mustjoki S; Leppä S
Haematologica; 2019 Feb; 104(2):338-346. PubMed ID: 30237271
[TBL] [Abstract][Full Text] [Related]
9. Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation.
Karn T; Pusztai L; Ruckhäberle E; Liedtke C; Müller V; Schmidt M; Metzler D; Wang J; Coombes KR; Gätje R; Hanker L; Solbach C; Ahr A; Holtrich U; Rody A; Kaufmann M
Eur J Cancer; 2012 Jan; 48(1):12-23. PubMed ID: 21741824
[TBL] [Abstract][Full Text] [Related]
10. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
[TBL] [Abstract][Full Text] [Related]
11. Construction of integrated microRNA and mRNA immune cell signatures to predict survival of patients with breast and ovarian cancer.
Ray M; Ruffalo MM; Bar-Joseph Z
Genes Chromosomes Cancer; 2019 Jan; 58(1):34-42. PubMed ID: 30285311
[TBL] [Abstract][Full Text] [Related]
12. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
[TBL] [Abstract][Full Text] [Related]
13. Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer.
Drakes ML; Mehrotra S; Aldulescu M; Potkul RK; Liu Y; Grisoli A; Joyce C; O'Brien TE; Stack MS; Stiff PJ
J Ovarian Res; 2018 May; 11(1):43. PubMed ID: 29843813
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of the immune microenvironment in ovarian cancer patients.
Yang L; Wang S; Zhang Q; Pan Y; Lv Y; Chen X; Zuo Y; Hao D
Mol Omics; 2018 Oct; 14(5):341-351. PubMed ID: 30129640
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis.
Yoshihara K; Tajima A; Komata D; Yamamoto T; Kodama S; Fujiwara H; Suzuki M; Onishi Y; Hatae M; Sueyoshi K; Fujiwara H; Kudo Y; Inoue I; Tanaka K
Cancer Sci; 2009 Aug; 100(8):1421-8. PubMed ID: 19486012
[TBL] [Abstract][Full Text] [Related]
16. Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer.
Zhang AW; McPherson A; Milne K; Kroeger DR; Hamilton PT; Miranda A; Funnell T; Little N; de Souza CPE; Laan S; LeDoux S; Cochrane DR; Lim JLP; Yang W; Roth A; Smith MA; Ho J; Tse K; Zeng T; Shlafman I; Mayo MR; Moore R; Failmezger H; Heindl A; Wang YK; Bashashati A; Grewal DS; Brown SD; Lai D; Wan ANC; Nielsen CB; Huebner C; Tessier-Cloutier B; Anglesio MS; Bouchard-Côté A; Yuan Y; Wasserman WW; Gilks CB; Karnezis AN; Aparicio S; McAlpine JN; Huntsman DG; Holt RA; Nelson BH; Shah SP
Cell; 2018 Jun; 173(7):1755-1769.e22. PubMed ID: 29754820
[TBL] [Abstract][Full Text] [Related]
17. A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer.
Kreuzinger C; Geroldinger A; Smeets D; Braicu EI; Sehouli J; Koller J; Wolf A; Darb-Esfahani S; Joehrens K; Vergote I; Vanderstichele A; Boeckx B; Lambrechts D; Gabra H; Wisman GBA; Trillsch F; Heinze G; Horvat R; Polterauer S; Berns E; Theillet C; Cacsire Castillo-Tong D
Clin Cancer Res; 2017 Dec; 23(24):7621-7632. PubMed ID: 28972047
[No Abstract] [Full Text] [Related]
18. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
[TBL] [Abstract][Full Text] [Related]
19. SCP-1 cancer/testis antigen is a prognostic indicator and a candidate target for immunotherapy in epithelial ovarian cancer.
Tammela J; Jungbluth AA; Qian F; Santiago D; Scanlan MJ; Keitz B; Driscoll D; Rodabaugh K; Lele S; Old LJ; Odunsi K
Cancer Immun; 2004 Oct; 4():10. PubMed ID: 15487888
[TBL] [Abstract][Full Text] [Related]
20. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
